Materials • Specialty Chemicals
$371.36 ▲ +26.15
(+7.58%)
MKT CAP: $14.75B • VOL: 690.6K
52W L $293 52W H $433
CSL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.02B | $5.00B | $4.59B |
| YoY Revenue Growth % | +0.3% | +9.1% | — |
| Gross Profit | $1.79B | $1.89B | $2.02B |
| Gross Margin % | 35.7% | 37.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.00B | $1.14B | $982.8M |
| Operating Margin % | 20.0% | 22.8% | 21.4% |
| Net Income (GAAP) | $740.7M | $1.31B | $767.4M |
| EBITDA (Normalized) | $1.11B | $1.23B | $1.15B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.10B | $1.03B | $1.20B |
| Capital Expenditures (CapEx) | $131.2M | $113.3M | $206.4M |
| Free Cash Flow (FCF) | $970.6M | $917.0M | $994.9M |
| FCF Margin % | 19.3% | 18.3% | 21.7% |
| Return on Invested Capital (ROIC %) | 22.2% | 25.1% | 15.8% |
| Cash & Short-Term Equivalents | $1.11B | $753.5M | $892.3M |
| Total Debt (Short + Long Term) | $2.88B | $1.89B | $1.90B |
| Total Stockholders' Equity | $1.80B | $2.46B | $3.89B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CSL.